SCHEMBL19031828

SCHEMBL19031828

CC(C(=O)OCCO)N1C(=O)CCC1=O

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 2/20 0.41
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 3/20 0.34
ATM Q13315 1/20 0.34
PKM P14618 1/20 0.33
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
MEN1 O00255 2/20 0.32
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28231228 0.78 SLC1A2 (0.40) SLC1A2ALDH1A1KMT2AATMPKM
SCHEMBL4522866 0.78 SLC1A2 (0.40) SLC1A2ALDH1A1KMT2AATMPKM
SCHEMBL21917309 0.78 SLC1A2 (0.39) SLC1A2ALDH1A1KMT2AATMPKM
SCHEMBL5590839 0.77 SLC1A2 (0.45) SLC1A2ALDH1A1KMT2AATMMEN1
Ethylene Glycol SCHEMBL3521351 0.76 SLC1A2 (0.47) SLC1A2ALDH1A1KMT2AATMPKM
SCHEMBL30327623 0.76 SLC1A2 (0.41) SLC1A2ALDH1A1KMT2AATMPKM
SCHEMBL28918361 0.75 MAPT (0.38) ALDH1A1KMT2AATMPKM
SCHEMBL3507385 0.75 KMT2A (0.40) SLC1A2ALDH1A1KMT2AATMPKM
SCHEMBL9351173 0.73 TSHR (0.34) ALDH1A1KMT2APKMTSHR
SCHEMBL26177011 0.70 ALDH1A1 (0.39) ALDH1A1KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3393496-A1 LONG-ACTING GLP-1R AGONIST AS A THERAPY OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS The Johns Hopkins University (US) 2018-10-31 EP disclosed
WO-2017112889-A1 LONG-ACTING GLP-1R AGONIST AS A THERAPY OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS THE JOHNS HOPKINS UNIVERSITY (US) 2017-06-29 WO disclosed